Dissecting the genetic and proteomic risk factors for delirium

Vasilis Raptis[1,2†], Youngjune Bhak[1], Timothy I Cannings[3], Alasdair M. J. MacLullich[4], Albert Tenesa[1,5†]

[1]The Roslin Institute, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Campus, Midlothian, UK

[2]Advanced Care Research Centre, School of Engineering, College of Science and Engineering, The University of Edinburgh, Edinburgh, UK

[3]School of Mathematics and Maxwell Institute for Mathematical Sciences, University of Edinburgh, UK

[4]Edinburgh Delirium Research Group, Ageing and Health, Usher Institute, University of Edinburgh, Edinburgh, Scotland, UK

[5]Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK

[†]Corresponding authors:

Vasilis Raptis

V.Raptis@sms.ed.ac.uk

Albert Tenesa

albert.tenesa@ed.ac.uk

Abstract

Delirium is an acute change in cognition, common in hospitalised older adults, and associated with high healthcare and human cost. In this work we shed light on the currently poorly understood genetic and proteomic background of delirium. We conducted the largest to date multi-ancestry analysis of genetic variants associated with delirium (1,059,130 individuals, 11,931 cases), yielding the *Apolipoprotein E* (*APOE*) gene as a strong risk factor with possible population and age-varying effects. *APOE* genetic effect on delirium remained significant after adjusting for dementia and Alzheimer disease (AD) and in dementia-free cohorts. A multi-trait analysis of delirium with AD identified 5 delirium genetic risk loci. Investigation of plasma proteins associated with up to 16-years incident delirium (32,652 individuals, 541 cases) revealed known and novel protein biomarkers, implicating brain vulnerability, inflammation and immune response processes. Incorporating proteomic and genetic evidence via mendelian randomisation, colocalisation and druggability analyses, we indicate putatively useful drug target proteins for delirium. Integrating proteins and *APOE* genetic risk with demographics significantly improved incident delirium prediction compared to demographics alone. Our results pave the way to better understanding delirium's aetiology and guide further research on clinically relevant biomarkers.

Delirium is a complex neurocognitive condition affecting nearly 25% of hospitalised older adults[1]. It

has a rapid onset, usually lasting from hours to days, and is characterised by an acute and often

reversible disturbance of attention, cognitive ability and awareness[2]. It is triggered mainly by acute

illness, surgery or injury. Delirium is strongly associated with multiple adverse outcomes, including

increased mortality, prolonged hospitalisation[3], and increased healthcare costs, with one study

estimating an annual cost of $182 billion dollars per year to European healthcare systems[4].

Delirium has a complex bidirectional relationship with dementia, in that people with dementia are

more likely to experience delirium in the context of an acute trigger, and delirium episodes are strongly

associated with future dementia risk[3,5]. There is some overlap in the clinical features of these

conditions, notably with respect to cognitive dysfunction, perceptual disturbances and sleep-wake

cycle changes[6]. However, the course of delirium is markedly different with respect to onset and

duration. The pathophysiology of delirium is complex and likely involves multiple potential

mechanisms[3]. Animal model and human biomarker studies implicate systemic inflammation triggering

neuroinflammation, disruption of the blood-brain barrier, and neuronal injury in delirium[3,7–9]. Aspects

of these mechanisms are also present in dementia, leading to the proposal that there may be shared

and potentially bidirectional pathology between delirium and dementia, such as neuroinflammation

leading to neurodegeneration[9,10].

Despite its high healthcare burden, however, current understanding of genetic and biological

mechanisms underlying delirium's pathophysiology is still limited, hindering personalised medicine

efforts to predict, prevent and treat the condition. Given delirium's increasing presence in the global

ageing population[6], alleviating its human and economic cost[11] through personalised medicine is all the

more important.

Previous studies on the genetic determinants of delirium have been small in scale and inconclusive[3,6,12],

largely focusing on a single or small sets of candidate genes[13–22]. The apolipoprotein E gene (*APOE*),

specifically its ε4 haplotype, is the most intensively studied gene[15,17,19–21], though clear conclusions on

its relationship with delirium remain lacking[6,23]. Advances in genome-wide association studies (GWAS)

over the last decades[24] have allowed researchers to search across the full spectrum of the human

genome for genetic risk factors involved in neurocognitive disorders[25–27], offering invaluable new

insights into disease mechanisms. However, research on delirium using these methods has lagged

behind other neurocognitive disorders, with only a few, relatively underpowered delirium GWAS

conducted to date[28–30]. Moreover, those studies did not address comprehensively the biological

implications of the potential gene-disease associations and were conducted primarily on individuals

of European descent.

Research on protein biomarkers for delirium has received increased attention recently, identifying
potential blood plasma, serum and cerebrospinal fluid (CSF) canditates[6,31]. Those biomarkers include
inflammatory proteins, such as interleukin-6 (IL-6) and C-reactive protein (CRP)[6,31,32], Alzheimer
disease pathology markers[6], and markers of neuronal injury, such as the neurofilament light chain
(NEFL)[9] and glial fibrillary acidic protein (GFAP)[8]. Previous studies however are limited in terms of
sample size and, often, the range of proteins tested.

In the current study we aim to upscale the efforts in identifying genetic and proteomic determinants
of delirium risk. To achieve this, we: (1) conducted the largest so far meta-analysis of delirium GWAS
datasets, the first to include individuals from diverse ancestries; (2) tested for plasma proteome
signatures of incident delirium for up to 16 years of follow-up in UK Biobank (UKB)[33] and triangulated
the results using genetically supported evidence from mendelian randomisation, colocalisation and
druggability analyses; (3) conducted a multi-trait meta-analysis between delirium and Alzheimer
disease, leveraging the shared genetic basis of the two conditions[6] and boosting the power to detect
genetic associations for delirium[34].

Results

***APOE* gene as delirium genetic risk factor**

To identify genetic variants associated with delirium, a multi-ancestry genome-wide association meta-
analysis (GWAMA) was conducted on eight sub-cohorts (Supplementary Table 1) from four global
ancestries: European (EUR, $n_{cases} = 7,988$, $n_{controls} = 549,568$, 52.6% of total sample size), Finnish
(FIN, $n_{cases} = 3,371$, $n_{controls} = 388,560$, 37%), African (AFR, $n_{cases} = 348$; $n_{controls} = 59,780$,
5.7%), South Asian (SAS, $n_{cases} = 107$; $n_{controls} = 9,356$, 0.9%) and admixed American / Hispanic
(AMR, $n_{cases} = 117$; $n_{controls} = 39,977$, 3.8%). Age distributions for the UK Biobank (UKB) and All of
Us Research Program (AoU) cohorts are presented in Supplementary Figure 1. In total, the GWAMA
comprised of up to 1,059,130 individuals and 11,931 delirium cases, yielding results for 24,951,028
single nucleotide polymorphism (SNP) genetic variants. The overall SNP heritability (h^2_{SNP}) of delirium
was estimated on the observed scale as $h^2_{SNP} = 0.0055$ ($standard\ error: 9x10^{-4}$; $p = 2.5x10^{-9}$),
significantly different from zero, and as $h^2_{SNP,l} = 0.029$ on the liability scale.

Variants at the *Apolipoprotein E* (*APOE*) gene and within its close genomic region on chromosome 19
(Figure 1) were significantly associated with delirium. The lead variant rs429358 (T>C, odds ratio [95%
Confidence Intervals]: 1.60 [1.55 − 1.65]; p = 9.7x10^-177) is an *APOE* missense variant, which together

with the rs7412 C>T variant forms the *APOE-ε4* haplotype (the rs429358-C and rs7412-C alleles), an

established risk factor for Alzheimer disease (AD)[35]. rs7412 also significantly associated with delirium

in our GWAMA (C>T, OR [95% CI]: 0.84 [0.79 – 0.88]; p = 1.8x10^{-11}).

Figure 1: Manhattan plot of the delirium multi-ancestry GWAMA. *Each point represents a genetic*

variant. The x-axis denotes the variant's genomic position and the y-axis the two-sided meta-analysis

association p-value. The grey dashed line denotes the genome-wide significance p-value threshold

5x10^{-8}. The gene in which the lead significant variant is located is annotated. GWAMA: genome-wide

association meta-analysis; APOE: Apolipoprotein E gene. The plot was created using the GWASLab

python package.

The lead variant rs429358 showed population specific genetic effects for delirium in the contributing

sub-cohorts (Figure 2). Significant associations were observed in all, except European (Michigan

Genomics Initiative (MGI), p = 0.27) and admixed American (AoU AMR, p = 0.12) populations from the

USA, with USA-based populations generally showing smaller effect sizes.

Cohort	Ancestry	N (cases)	N	Odds Ratio (95% CI)	p-value
UKB	EUR	7,176	392,273	1.68 (1.61-1.75)	1.6e-137
AllofUs	EUR	652	120,457	1.25 (1.08-1.46)	0.003
MGI	EUR	160	44,772	1.20 (0.87-1.67)	0.27
FinnGen	FIN	3,371	391,931	1.59 (1.50-1.69)	2.5e-52
UKB	AFR	115	7,595	1.44 (1.06-1.97)	0.02
AllofUs	AFR	233	52,531	1.10 (0.88-1.38)	0.40
UKB	SAS	107	9,463	1.83 (1.13-2.95)	0.01
AllofUs	AMR	117	39,971	0.72 (0.48-1.09)	0.12
Overall		11,931	1,059,110	1.60 (1.55-1.65)	9.7e-177

Heterogeneity: I^2 =84% (P = 2.3e-07)

Figure 2: Associations between the GWAMA lead variant and delirium risk for each cohort.

Forrest plot showing the cohort-specific association results for the rs429358 T>C lead variant with delirium. Effect sizes for the C allele and corresponding two-sided p-values are shown for each contributing sub-cohort and the overall meta-analysis. Grey dotted lines separate results for each ancestry group. GWAMA: genome-wide association meta-analysis; UKB: UK Biobank; MGI: Michigan Genomics Initiative; N: sample size; CI: 95% confidence intervals for the odds ratio; EUR: European; FIN: Finnish; AFR: African; SAS: south Asian; AMR: admixed American).

Conditional GWAS analysis on the *APOE*-ε4 haplotype resulted in all variants on the *APOE* region losing significance (Supplementary Figure 2), suggesting that *APOE*-ε4 is the sole independent genetic risk factor in the region. On the same analysis, an intronic variant within the *ADAM32* gene on chromosome 8 gained significance (rs531178459; p = 3.3x10^{-8}).

Furthermore, using a series of sensitivity analyses in UKB (see Methods and Supplementary Table 2), we tested to what extent the observed *APOE* association with delirium is driven by underlying dementia. Variants in the *APOE* region remained significant after adjusting for dementia status in the delirium GWAS (Supplementary Figure 3). Specifically, the lead variant from the unadjusted GWAMA, rs429358, showed again a strong association (OR [95% CI]: 1.20 [1.12 – 1.28]; p = 3.7x10^{-15}). Variants on the *SEC14L1* gene on chromosome 17 were also significant in the dementia-adjusted analysis. rs429358 remained significant in GWAS conducted on dementia-free (OR [95% CI]: 1.27 [1.2 – 1.34]; p = 4.7x10^{-18}; Supplementary Figure 4) and AD-free (OR [95% CI]: 1.45 [1.38 – 1.52]; p = 3.9x10^{-56}; Supplementary Figure 5) stratified cohorts. rs429358 genetic signals in dementia-adjusted and dementia/AD-free GWAS were replicated in AoU (Supplementary Table 2). The *APOE* genetic signal

161   remained highly significant in an age-stratified GWAS, on participants with age 60 years or more (OR

162   [95% CI]: 1.7 [1.63 – 1.77]; p = 2.7x10^{-141}; Supplementary Figure 6 and Supplementary Table 2).

Multi-trait analysis between delirium and Alzheimer disease

We found a significant genetic correlation (r_g) between delirium and Alzheimer disease (AD), $r_g =$

$0.38\ (SE: 0.12;\ p = 1.9x10^{-3})$, pointing out to a partially shared genetic architecture. Given this, we

further conducted a multi-trait analysis of GWAS summary statistics (MTAG) between delirium and

AD. MTAG can increase statistical power to detect new genetic associations, by leveraging the shared

genetic information between related traits[34]. Our MTAG analysis identified 10 independent genetic

loci associated with delirium, of which 5 replicated in the held-out set (Figure 3 and Supplementary

Table 3). The closest genes mapped to the lead replicated variants included: *CR1* (rs4844610 A>C; OR

[95% CI]: 1.01 [1.006 - 1.014]; p = 1.4x10^{-8}), *BIN1* (rs6733839 T>C; OR [95% CI]: 1.015 [1.012 - 1.018];

p = 7x10^{-25}), *CLU* (rs2279590 T>C; OR [95% CI]: 0.992 [0.989 – 0.995]; 4.2x10^{-8}), *MS4A4A* (rs1582763

A>G; OR [95% CI]: 0.991 [0.988 - 0.994]) and *TOMM40* (rs117310449 T>C; OR [95% CI]: 1.09 [1.07 -

1.1];p =7x10^{-38}).

Figure 3: Manhattan plot of the multi trait analysis of GWAS between delirium and Alzheimer disease. *Delirium-specific MTAG summary statistics are shown. Each point represents a genetic variant. The x-axis denotes the variant's genomic position and the y-axis the MTAG association p-value (two-sided) in the discovery set. The grey dashed line denotes the genome-wide significance p-value threshold 5x10^{-8}. The closest gene in which the lead significant variant is located is annotated. Red colour highlights loci ±1,000kb around lead variants that replicated. MTAG: Multi-trait analysis of GWAS. The plot was created using the GWASLab python package.*

184 Four out of five of the lead replicated MTAG signals were also significant in the original delirium
185 GWAMA (Supplementary Table 3), with rs2279590 (*CLU* gene) being marginally non-significant (p =
186 0.058). Effect sizes were consistent between MTAG and delirium GWAMA results. Variants in the *APOE*
187 genomic region that were significant in our delirium GWAMA were also significant in MTAG.

Mediation analysis

We implemented a mediation analysis in order to estimate how much of the *APOE-ε4* genetic effect
on delirium is mediated by dementia, adjusted for age and sex (Figure 4). We found that *APOE-ε4*
exerts a significant direct effect on delirium in a dose-dependent way: $OR_{\text{direct effect (0vs1)}}$ [95% CI]: 1.14
[1.08 - 1.2]; p = 4.5×10^{-7}; for one *APOE-ε4* copy, and $OR_{\text{direct effect (0vs2)}}$ [95% CI]: 1.29 [1.15 - 1.45]; p =
1.7×10^{-5} for two *APOE-ε4* copies. The *APOE-ε4* total effect on delirium was partially mediated by
dementia ($OR_{\text{indirect effect (0vs1)}}$ [95% CI]: 1.39 [1.36 - 1.42]; p = 1.1×10^{-237}; and $OR_{\text{indirect effect (0vs2)}}$ [95% CI]:
2.59 [2.47 – 2.77]; p = 2.1×10^{-233}), with the direct effect accounting for 29% and 21% of the total effect
for one and two *APOE-ε4* copies respectively. These results further support the role of *APOE* gene on
delirium, independently of dementia.

198
Figure 4: Mediation analysis of APOE-ε4 on delirium, mediated by all-cause dementia. (a)
Hypothesised directed acyclic graph, showing all-cause dementia as mediator of APOE-ε4 genetic
effect on delirium (black arrows), adjusted for baseline covariates: age and sex (grey arrows). ***(b,c)***
Effect decomposition of the total APOE-ε4 effect, into natural direct (independent of dementia) and
natural indirect (mediated through dementia) effects. ***(b)*** *shows the effect of having one APOE-ε4*

haplotype, and (c) the effect of having two APOE-ε4 haplotypes, compared to having none. OR: odds

ratio. NDE: natural direct effect; NIE: natural indirect effect.

Our sensitivity analysis regarding the role of unmeasured confounding suggests that, an unmeasured

confounder associated with both dementia and delirium with approximate effect sizes of 1.54 each,

over and above the measured covariates, could suffice to completely explain away the observed direct

effect of one *APOE-ε4* copy on delirium, but weaker confounding could not[36]. Respectively, the

minimum unmeasured confounder effect size would need to be 1.9 to completely explain away the

direct effect of two *APOE-ε4* copies.

Finally, a mediation analysis further adjusting for cognitive function, socioeconomic deprivation and

chronic disease burden, on top of age and sex, still detected a significant direct effect of *APOE-ε4* on

delirium: OR $_{direct\ effect\ (0vs1)}$ [95% CI]: 1.12 [1.01 - 1.25]; p = 0.038 (32% of the total effect) for one *APOE-*

ε4 copy, and OR $_{direct\ effect\ (0vs2)}$ [95% CI]: 1.55 [1.18 - 2.06]; p = $2x10^{-3}$ (34% of the total effect) for two

APOE-ε4 copies respectively (Supplementary Figure 7).

Protein risk factors for incident delirium

A proteome-wide association study (PWAS)on 32,652 European UKB participants (541 cases) revealed

109 out of the 2,919 total proteins, whose plasma levels were significantly associated with incident

delirium up to 16-years of follow-up (Figure 5a and Supplementary Table 4) at a Bonferroni adjusted

p-value threshold (p = $1.7x10^{-5}$). The APOE protein had a negative effect on incident delirium risk,

meaning that higher plasma levels of the protein are associated with reduced future risk. The

association was significant at the nominal level (0.05), but not after multiple test correction (OR [95%

CI]: 0.86 [0.79 - 0.94], p = $7x10^{-4}$, Supplementary Table 4).

Figure 5: Associations of plasma proteins with incident delirium. *Volcano plot showing the proteome-wide associations of 2,919 plasma proteins with incident delirium in (**a**) the non-stratified, and (**b**) the dementia-free UKB proteomic set. Odds ratios of the logistic regression models are plotted on the x-axis and respective two-sided $-\log_{10}$(p-values) on the y-axis. All models are adjusted for age at protein collection, sex and BMI. The black dashed horizontal line indicates the Bonferroni adjusted p-value threshold: 1.7×10^{-5}, with proteins above this line colored red. The grey dashed horizontal line indicates the nominal p-value threshold: 0.05. The plot was created using the EnhancedVolcano R package (v1.18.0).*

Further adjusting the individual protein models for *APOE*-ε4 status did not substantially alter the results (Supplementary Table 5), having highly correlated effect size estimates with the models adjusted only for age, sex and BMI (Pearson's correlation r=0.99). Additionally including a protein* *APOE*-ε4 interaction term also yielded highly similar results (main effect correlation r=0.93). No significant protein* *APOE*-ε4 interaction has observed at a Bonferroni adjusted threshold of p-value < 1.7×10^{-5} (Supplementary Table 6).

The 109 proteome-wide significant proteins were found to be significantly enriched (q-value < 0.05) in several important inflammation and immune response biological pathways, such as interleukin and Tumour Necrosis Factor (TNF) signalling (Supplementary Table 7).

Restricting our PWAS on the dementia-free subset of UKB (31,692 participants; 349 delirium cases), reduced the number of proteins significantly associated with incident delirium to 75 (Figure 5b and Supplementary Table 8). Notably, the APOE plasma protein, although still had a negative effect size,

249 lost nominal significance and had reduced magnitude that in the non-stratified PWAS (OR [95% CI]:
250 0.97 [0.87 – 1.08]; p = 0.63).

Protein selection and prediction models

A machine learning framework was applied to further pin down which plasma proteins are robustly
associated with incident delirium. Our approach, based on LASSO regularised regression[37] and stability
selection[38], revealed 19 proteins (stability-selected proteins, Supplementary Table 9) consistently
selected as predictive of incident delirium in the training set. All of the stability-selected proteins
represent a subset of the top individually significant proteins identified through the proteome-wide
association analysis. The FGL1 protein was removed from subsequent analyses, as it had a non-
significant contribution to the re-fit prediction models and was dropped during stepwise regression.
The 18 remaining stability-selected proteins provide marginal prediction improvements of incident
delirium on an independent test set, compared to predictions based on demographic factors alone
(Figure 5 and Supplementary Tables 10-11). Specifically, adding the 18 stability-selected proteins to
the "basic" model that includes age, sex and BMI as predictors increased the AUC from 0.764 to 0.791,
but the increase was not significant (DeLong test p-value = 0.09, Supplementary Table 11). However,
adding proteins and *APOE*-ε4 status to the basic model showed a significant prediction improvement
(AUC from 0.764 to 0.794, p = 0.049, Supplementary Table 11). Finally, the model fit only with the
selected proteins performed worse that the basic model (AUC from 0.764 to 0.729, p = 0.21, Figure 5a
and Supplementary Table 11). The precision-recall performance showed similar pattern (Figure 5b),
with the full models having higher PR-AUC: 0.065 and 0.06 for the "*APOE*+proteomic+basic" and the
"proteomic+basic" models respectively, compared to 0.043 for the basic model.

We repeated our protein selection and prediction framework in the dementia-free sub-cohort of the
UKB proteomic set. 14 out of the 19 stability-selected proteins still had a significant effect on incident
delirium in the training set (Supplementary Table 9). However, only the AREG and MSLN proteins were
consistently selected in the dementia-free sub-cohort (selection frequency > 0.5). We still observed a
marginally better prediction of incident delirium on the test set using *APOE*-ε4 and the 14 stability-
selected proteins on top of demographic factors (AUC from 0.758 to 0.79, p = 0.13; PR-AUC from 0.033
to 0.036) (Supplementary Figure 8 and Supplementary Table 10), although now with a non-significant
AUC improvement.

Figure 6: Proteomic predictive performance on test set. Receiver Operating Characteristic (ROC) (a)

and Precision-Recall (PR) curves (b) showing performance metrics of different models for predicting

incident delirium on the held-out test set. The "proteomic" logistic regression model is fit with the 18

stability-selected proteins, the "basic" model is fit using only age at protein collection, sex and BMI and

the "proteomic+basic" includes both. The "APOE+proteomic+basic" model additionally includes APOE-

ε4 haplotype count as predictor. The dotted black lines indicate the performance of a randomly

classifying model, that is the diagonal of the ROC curve (a) and the disease prevalence horizontal line

in the PR curve (b). AUC: Area Under the Curve. ROC and PR plots and AUC calculations are made using

the yardstick R package (v1.3.0).

Mendelian randomisation

We performed mendelian randomisation (MR), to test for causal associations between 1,989 plasma

proteins (exposures) and delirium (outcome). We found 53 proteins causally associated with delirium

at a false discovery rate (FDR) q threshold < 0.05 using inverse variance weighted (IVW) or Wald ratio

MR. (Figure 7 and Supplementary Table 12). Out of the 53 MR significant proteins, DSC2 was the only

one with a significant association in our PWAS analysis of protein risk factors (Figure 5) and a

consistent direction of effect. Using a less strict FDR q < 0.05 threshold in our PWAS, 7 additional

proteins were identified (ADAM8, APOE, DPP10, DSC2, LAYN, NT5C1A, PILRA and PVR) that were

significant in both the PWAS and MR. At a nominal PWAS p-value level ($p < 0.05$), three more proteins

(CCL25, PON3 and GGH) overlapped the significant MR results. Four of the above PWAS - MR

overlapping significant proteins successfully replicated in our FinnGen replication MR: GGH, PVR,

APOE and PILRA (Figure 7). All of the replicated delirium-associated proteins were also significant using

sensitivity MR methods (weighted median, maximum likelihood and MR-Egger; $p < 0.05$)

(Supplementary Table 13). The MR-Egger intercept test did not reveal evidence of horizontal

pleiotropy ($p > 0.05$). Genetic variant heterogeneity was suggested by the Cochran's Q test ($p < 0.05$)

for the genetic instruments used in the APOE and PVR MR (Supplementary Table 13). Repeating MR

for these two proteins using more strictly independent pQTLs ($r^2 < 0.001$), APOE did not show evidence

for heterogeneity (Q test $p = 0.37$), while its causal effect on delirium remained significant (IVW MR

beta (standard error) = -0.57 (0.03), $p = 1.13 \times 10^{-78}$). For PVR, heterogeneity remained high (Q test $p =$

0.03), and lost significance for its causal effect (IVW MR beta (SE) = 0.06 (0.06), $p = 0.34$), suggesting

that PVR's initially observed significant MR effect may be driven by pleiotropy and linkage

disequilibrium of its genetic instruments with the *APOE*-ε4 haplotype that is located in close proximity.

Using delirium in the dementia-free UKB GWAS as outcome, ADAM8, CCL25, PILRA, and LAYN lost their

MR causal effect significance (FDR $q > 0.05$). A summary of analyses supporting each protein's

association with delirium is presented in Table 1, with full summary results in Supplementary Data 1.

Figure 7: Mendelian randomisation results of plasma proteins on delirium. *MR associations were derived using the IVW or Wald ratio method and UKB delirium GWAS summary statistics. Only significant (FDR q < 0.05) MR associations are shown (IVW/Wald ratio betas and 95% confidence intervals). Replication MR was conducted using delirium GWAS summary statistics from Finngen. Colors are assigned to proteins based on their significance in the PWAS analysis: Bonferroni: p < 1.7x10^-5; FDR: q < 0.05; nominal: p < 0.05 and having consistent direction of effect. MR: mendelian randomisation; PWAS: proteome-wide association study; FDR: false discovery rate. IVW: inverse variance weighted.*

329 **Table 1: Overview of follow-up analyses on proteins significantly associated with delirium through PWAS and MR.**

Protein	Effect direction	PWAS significance	Discovery MR (UKB)							Replication MR IVW (FinnGen)	Co-localisation	Druggability Tier
			IVW	IVW dementia-free	Weighted median	Maximum Likelihood	MR-Egger	MR-Egger intercept test	Cochran's Q test			
PON3	-	Nominal	✓	✓	✓	✓	✓	✓	✓	✗	✗	Tier 1
ADAM8	+	FDR	✓	✗	✓	✓	✗	✓	✓	✗	✗	Tier 2
GGH	+	Nominal	✓	✓	✓	✓	✓	✓	✓	✓	✓	Tier 2
PVR [a]	+	FDR	✓	✓	✓	✓	✓	✓	✗	✓	✗	Tier 3A
APOE [b]	-	FDR	✓	✓	✓	✓	✓	✓	✗	✓	✓	Tier 3A
DPP10	+	FDR	✓	✓	✓	✓	✗	✓	✓	✗	✗	Tier 3B
CCL25	+	Nominal	✓	✗	✓	✓	✓	✓	✓	✗	✗	Tier 3B
DSC2	+	Bonferroni	✓	✓	✓	✓	✗	✓	✓	✗	✗	Not classified
NT5C1A	+	FDR	✓	✓	✓	✓	✗	✓	✓	✗	✗	Not classified
PILRA	+	FDR	✓	✗	✓	✓	✓	✓	✓	✓	✗	Not classified
LAYN	+	FDR	✓	✗	✗	✓	✗	✓	✓	✗	✗	Not classified

Proteins that were supported by both the PWAS (p < 0.05) and MR via IVW or Wald ratio (FDR < 0.05) analyses in UKB and had consistent effect direction are

shown. ✓ (green) denotes significance (p < 0.05) in the MR sensitivity analyses (Weighted median, Maximum Likelihood and MR-Egger); non-significance in

the MR-Egger intercept and Cochran's Q tests (p > 0.05); and PP.H4 > 0.8 in the colocalisation analysis. ✓ (orange) denotes suggestive colocalisation: 0.8 >

PP.H4 > 0.5 ✗ denotes failure. Full summary statistics are available in Supplementary Data 1. PWAS: proteome-wide association study; MR: mendelian

randomisation; FDR: false discovery rate; IVW: inverse variance weighted; UKB: UK Biobank; pQTL: protein Quantitative Trait Loci

[a] PVR lost MR significance and showed high heterogeneity using strictly independent pQTL (r² < 0.001).

[b] APOE remained significant in MR and did not show heterogeneity evidence using strictly independent pQTL (r² < 0.001).

Colocalisation

We further conducted colocalisation analysis to test whether the protein and delirium genetic effects are exerted by the same rather than distinct genetic variants in each genomic region. 37 proteins colocalised with delirium within the *APOE* genomic region (Supplementary Table 14 and Supplementary Data 2) with high probability (posterior probability of a shared causal variant, PP.H4 > 0.9 as per coloc software notation[39]). 30 more proteins showed suggestive evidence of colocalisation with delirium throughout the genome (PP.H4 > 0.5). It should be noted that colocalisation methods are generally not well powered to detect shared casual genetic signals unless both traits shown strong genetic support (i.e. GWAS $p < 5 \times 10^{-8}$)[39,40]. Here, only the *APOE* region is strongly associated with delirium, thus many colocalisation signals in other parts of the genome may be missed.

Druggability assessment

For delirium-associated proteins with support from both our PWAS and MR analyses, we assessed their suitability to act as drug targets (Table 1). We used the "druggable genome" curated by Finan et al (2017)[41], a resource which stratified human proteins on tiers based on the strength of their druggability evidence (see Methods). Of the selected proteins, PON3 belonged in the druggability tier 1 (targets of approved drugs or clinical-phase drug candidates); ADAM8 and GGH belonged in tier 2 ("targets with known bioactive drug-like small-molecule binding partners"[41] or having high similarity with approved drug targets); PVR, APOE, DPP10, CCL25 in tier 3 (secreted or extracellular proteins, proteins with medium similarity to approved drug targets, and members of key druggable gene families not included in tiers 1 or 2[41]). DSC2, NT5C1A, PILRA, LAYN did not have druggability information.

KGWAS

Knowledge Graph GWAS (KGWAS) analysis of our GWAMA summary statistics revealed 4 disease-critical genes within the *APOE* genomic region (*APOE*, *TOMM40*, *PVRL2*, *BCAM*), prioritized via functional genomics knowledge graph[42]. All of the KGWAS-identified significant SNPs were also significant in our GWAMA (Supplementary Table 15).

Discussion

In this analysis we conducted the largest to our knowledge multi-ancestry genome-wide meta-analysis on delirium. Genetic variants on the *APOE* gene on chromosome 19 were identified as significantly associated with delirium, with the top variant hit, rs429358, showing population-specific association

patterns. The *APOE* gene encodes for APOE, a lipid transporter protein in the periphery and the brain. APOE is a strong risk factor for Alzheimer Disease (AD), through its diverse roles in pathways such as amyloid-β plaque deposition, neuroinflammation and dysregulation of lipid metabolism in the brain[43].

The role of *APOE* gene in delirium is currently unclear, with previous meta-analyses reporting no association between *APOE* and delirium[12,23]. In UKB, a previous study on European participants found an association between *APOE*-ε4 status and delirium (hazard ratio = 3.73 [2.68 - 5.21])[44]. It has been suggested that interactions between *APOE*-ε4 and inflammation-related proteins can drive delirium development[6]. To assess this hypothesis, we tested whether the interaction term between each plasma protein level and *APOE*-ε4 status significantly associated with incident delirium (Supplementary Table 5). No protein*APOE*-ε4 interaction reached significance adjusted for multiple testing (p-value threshold = 1.7×10^{-5}). However, the CEND1 protein exhibited an interaction with *APOE*-ε4 marginally below threshold (beta$_{(interaction)}$ [95% CI] = 0.27 [0.10 − 0.42]; p$_{(interaction)}$ = 8×10^{-4}). CEND1 is a mitochondrial neural differentiation protein, expressed in the nervous system[45]. It has previously been implicated in cognitive impairment in mice[45] and AD in human[46] brains. Additionally, *APOE*-ε4 expression in astrocytes has been implicated in impaired mitochondrial function[47], although to our knowledge CEND1 and APOE have not been linked in previous studies. CEND1 role in delirium has also not been investigated so far.

Ancestry-dependent *APOE*-ε4 genetic effects on delirium have not been systematically assessed previously. For AD, the risk conferred by *APOE*-ε4 varies by ancestral background, with African/African Americans and Hispanics having less pronounced risk than white Europeans and Asians[48,49]. Additionally, higher *APOE*-ε4 expression levels have been observed in carries of European compared to African ancestry[50]. Here, findings suggest a similar pattern, that is rs429358-C having a higher effect in European, Finnish and south Asian populations than African and Hispanic/Admixed American. Overall, sub-populations from the USA (AoU, MGI) have weaker *APOE* effects than those from the UK or Finland (UKB, FinnGen). This might reflect the younger age of participants in USA-based studies (Supplementary Table 1) or phenotypic differences in delirium diagnoses across the healthcare systems of different countries. Age-dependent genetic effects have been previously described for *APOE*-ε4 with regard to AD[48,51] and progression to mild cognitive impairment and AD[52], showing increasing effects until an age of 70 − 75, with reduced effect on later ages[48,51,52].

It is also possible that underlying dementia is driving the strong association between *APOE* and delirium observed here. 36% of UKB European delirium cases had a dementia diagnosis, compared to 1.4% in the control group (Supplementary Table 1). This is to be expected given the close relationship of the two disorders[6], but it may hide delirium specific genetic effects and overemphasize the role of

APOE. To this end, *APOE* remained significant in our range of sensitivity analyses – GWAS adjusting for
all-cause dementia (Supplementary Figure 3), mediation analysis (Figure 4), dementia and AD
stratified GWAS (Supplementary Figure 4-5 and Supplementary Table 2) – although with weaker
effect. This result may suggest that *APOE* association with delirium is not entirely through its role in
dementia or AD.

Regarding our mediation analysis, it should be noted that unmeasured confounding could bias the
estimate of *APOE's* direct effect on delirium[36,53] (see Methods section). Unmeasured confounding
between *APOE* (exposure) and dementia (mediator) or delirium (outcome) could be introduced by
residual population stratification or linkage disequilibrium between *APOE-ε4* and linked causal genetic
variants. It is also possible that *APOE*-induced pleiotropic genetic effects can confound the delirium-
dementia relationship, also introducing bias. Our results remained significant after adjusting for
possible confounders between dementia and delirium, i.e. shared risk factors such as cognitive
function, socioeconomic deprivation and comorbidity burden[3–5,54,55]. None of the additional
confounders had an independent odds ratio effect on both delirium and dementia above 1.54 each,
the minimum required to explain away the observed *APOE* direct effect on delirium. However, some
residual confounding may still remain, for example due to precipitating factors of delirium episodes
during hospitalisation, such as infections, medication status, sleep disruptions or severity of
presenting illness. These factors have been previously estimated to have a strong effect on delirium[3,4],
and may be also related to dementia[55]. Assessing the effect of those factors was outside the scope of
our study.

Adjusting for *APOE-ε4* attenuated the genetic effects within the whole *APOE* region. This observation
suggests that the significance of the genetic variants in the close proximity is driven by linkage
disequilibrium with the *APOE-ε4* haplotype, not secondary independent signals. Moreover, an intronic
variant on the *ADAM32* gene gained significance after adjusting for *APOE-ε4*. *ADAM32* belongs to the
ADAM family of metalloproteinases, some of which have been implicated in AD[56]. ADAM proteins are
involved diverse functions, including immunity related pathways[57].

Regarding our multi-trait analysis of delirium with AD (MTAG), five genetic loci were found to have a
significant effect on delirium, supported by replication in the AoU EUR cohort. Among the replicated
loci, several important AD risk genes[58] were detected: *BIN1*, *CLU*, *CR1*, *MS4A4A*, *TOMM40*. The
MS4A4A gene is expressed in macrophages and has been linked with AD[59], vascular dementia and
systemic lupus erythematosus[60]. The lead variant's minor allele on the *MS4A4A* gene, rs1582763, has
been previously associated with decreased risk of AD[59]. This variant's association with delirium has
not been reported before, but we also found a protective effect of the rs1582763 minor allele on

delirium. *BIN1* has been recently implicated in the regulation of calcium homeostasis in glutamatergic neurons, and its expression in AD human brains is reduced comparted to healthy brains[61]. The clusterin gene (*CLU*), also named Apolipoprotein J (*APOJ*) codes for a multifactorial protein, with apparent role in neurodegenerative diseases[62]. *CLU*, much like *APOE* is thought to be involved in amyloid-β plaque deposition in AD pathologies. With regard to delirium, protein expression of apolipoproteins including CLU and APOE were previously found to be downregulated in the cerebrospinal fluid (CSF) of delirium subjects compared to mild AD controls[63]. In our proteomic analysis, CLU protein levels were also downregulated in incident delirium subjects' plasma (Supplementary Table 3), but not significantly so (p-value > 0.05). This discrepancy may reflect different CLU protein abundance between CSF and plasma tissues. The *CR1* gene, implicated in complement activation, is believed to exert its role to AD pathogenesis through amyloid-β clearance, neuroinflammation and tauopathy (the deposition of abnormal tau protein in the brain)[64]. To the best of our knowledge, the role of *CR1* in delirium has not been investigated previously. In our study, CR1 plasma protein levels had a nominally significant association with incident delirium (p-value = 0.013). *TOMM40* genetic variants have been associated with AD before[65]. Given *TOMM40*'s close proximity and high linkage disequilibrium with the *APOE* gene, its role in AD has frequently been contested[65]. However, it has also been suggested that *TOMM40* independently affects AD risk through its role in regulating protein transportation in the mitochondria[65,66]. *TOMM40* has not been previously implicated in delirium. Overall, given the small effect sizes of the MTAG-identified genes for delirium (Supplementary Table 2), and their prominent role in AD, it may be possible that their significance in our analysis is mainly driven due to their role in AD. Nonetheless, our findings suggest novel genes (e.g. *MS4A4A*, CR1, *TOMM40*) that may be of relevance to future delirium research and therapeutic targets investigations.

Previous proteomic studies for delirium have, to our knowledge, focused on the protein landscape shortly before or following delirium episodes[31]. Here, an important novelty of our proteomic study is the large follow-up period between protein measurements and delirium incidence (median time to first delirium event: 11.4 years, interquartile range (IQR) [9.5-12.7]), allowing identification of relevant biomarkers and biological mechanisms at an early stage, such as several neurologically relevant and immune system related proteins.

For example, we found plasma GFAP and NEFL levels – biomarkers of neuronal injury – to be associated with incident delirium. Previous research paints a complex, possibly bidirectional relationship between neuronal injury and delirium. Increased plasma and CSF NEFL levels, a marker of neuroaxonal injury, have been observed in delirium patients pre- and postoperatively[6,8,9,67,68]. It is unclear however whether this is due to underlying neurodegeneration (e.g. due to preclinical

dementia) or a feature of delirium[6]. In our proteomic analyses we observed significant and consistent

effect of NEFL on incident delirium in both the full and dementia-free populations. This may implicate

neuroaxonal injury as an underlying driver of delirium independently of dementia-related

neurodegeneration, even long before hospitalisation. Our findings, thus, add support for the role NEFL

as a useful predictive biomarker for delirium[6].

GFAP is an astrogliosis marker, that is an increase of astrocytes levels in the central nervous system in

response to injury. High GFAP levels have been observed previously in post-mortem brains of delirium

cases[69], CSF of persistent delirium[8], blood and CSF of delirium patients undergoing elective surgery[32,67].

In our analysis, GFAP, was only predictive of incident delirium in our full proteomic set (Supplementary

Table 4), not in the dementia-free population (Supplementary Tables 8-9). This may indicate that, in

the years preceding delirium, astrogliosis is only relevant for delirium in the context of underlying

dementia. GFAP may be more useful as a delirium biomarker in the short term, possibly in patients

with traumatic brain injury or underlying neurodegeneration.

Systemic inflammation markers have been observed among the delirium-associated proteins in our

study. For instance, C7, BTLA, FGL1 participate in the immune response, whereas LRG1 and LTA4H in

inflammatory processes. LRG1 has been implicated in brain injury after sepsis in mice[70], sepsis being

a main driver of delirium aetiology[3]. Interleukins (IL), identified through our enrichment analysis, play

an important role in regulating immune response and inflammation and have frequently been

implicated in delirium[71,72]. Indeed, IL-6 – found to have a strong delirium association in our proteome

wide association study – is among the most consistently identified biomarkers of delirium and markers

of postoperative cognitive decline[31,32]. All of the inflammatory related proteins were significant in our

dementia-free sensitivity analyses, suggesting a role for delirium partially independent of dementia

pathology.

Other notable proteins robustly associated with delirium in our proteomic analysis are BCAN,

SELENOP, AREG and MSLN. BCAN, a protein with a role in brain extracellular matrix formation, has

been observed to be downregulated in brains of post-infection delirium and in AD patiens[73]. Lower

plasma levels of SELENOP, an important selenium transporter in the brain has been associated with

worse global cognition and AD[74]. Here, to the best of our knowledge, is the first time that an

association between SELENOP and delirium has been reported. The associations of AREG and MSLN

with delirium were also novel findings. AREG is a member of epidermal growth factor protein family,

involved in many aspects of cell proliferation[75]. Possible mechanisms linking AREG to delirium could

include neuroinflammation and regulation of T cells in astrocytes in sepsis-associated delirium[76], type

2 inflammatory response and tolerance against pathogens[77], or tumor development[75]. MSLN is a

mesothelial cell surface glycoprotein, overexpressed in many cancers[78]. Delirium is common in cancer

patients, arising either as a complication of the disease or indirectly through medical and surgical

intervention for cancer treatment[79]. Further research on the overlapping pathophysiology between

delirium and cancer (e.g. shared biomarkers[80]) is important for better management of delirium

throughout cancer care trajectories[79].

Overall, our proteomic analysis results align with the proposed mechanisms of delirium

pathophysiology, that is brain vulnerability - indicated by brain injury marker proteins -, systemic and

nervous system inflammation being driving factors for delirium[3,6]. At the same time, our results could

inform future research in delirium prediction biomarkers, some of which are novel in delirium research

(e.g SELENOP, CEND1, AREG and MSLN).

Our findings have notable clinical and biological clinical implications. We found that *APOE-ε4* is a

robust genetic risk factor, remaining significant after adjustment for presence of dementia. The

findings suggest that *APOE-ε4* confers vulnerability to adverse acute brain changes induced by triggers

of delirium. Indeed, it is known that *APOE-ε4* is associated with exaggerated neuroinflammatory

responses[81], altered blood brain barrier integrity[82,83], increased beta-amyloid accumulation following

various injuries[84], and increased white matter pathology[85]. *APOE-ε4* therefore could contribute to

increased risk of delirium, and also cause or amplify neuropathological changes linked with dementia.

A key next step is to test whether *APOE-ε4* carriers are disproportionately likely to develop new

dementia after a delirium episode, even in the absence of prior cognitive impairment.

Clinically, *APOE-ε4* status has potential to assist in stratification for delirium prevention trials, in

prediction of dementia following delirium, and as a target for neuroprotective therapies during acute

illness especially if delirium is present. Animal studies targeting APOE have shown encouraging results

in terms of improving AD phenotypes[83]. Some promising therapeutic approaches include increasing

APOE levels and lipidation, APOE mimetics (small peptides mimicking APOE's receptor-binding

structure) and *APOE-ε4* gene therapy[43,83]. However, therapeutic translation in human clinical trials is

still limited[83]. A currently unpublished phase 2 clinical trial (NCT03802396)[86] found that administration

of CN-105 – an APOE mimetic drug – lowered postoperative delirium incidence and severity compared

to administration of placebo, but not significantly. Further clinical research is needed in order to clarify

the therapeutic potential of APOE targeting therapies.

In terms of delirium treatment, we explored whether our identified proteins could be suitable drug

targets. For this, we triangulated our proteomic study findings with proteome-wide mendelian

randomisation (MR) and colocalisation analyses. Incorporating genetics in drug target identification,

e.g. through MR, is particularity attractive, as drugs with genetic support are more likely to be

successful in clinical trials[87,88] or can offer drug repurposing opportunities[89]. Our druggability

assessment found PON3 as an notable drug target for delirium. PON3 is a secreted high density

lipoprotein-associated enzyme[90], participating in the metabolism of the statin lovastatin, a licenced

lipid-lowering medication. The role of statins in delirium management is unclear. Statin usage has

been associated with improved delirium outcomes in randomised controlled trials and observational

studies, but overall evidence is inconsistence, with a recent meta-analysis finding no significant

protective effect and high heterogeneity[91]. In our analysis, increased PON3 plasma level was found to

have protective effect against delirium. This is consistent with high PON3 levels being protective

against atherosclerosis and cardiovascular disease[92], possibly through its antioxidant action[92,93]. It is

not clear, however, how PON3 levels can affect statin metabolism. It may be possible that PON3 can

affect lovastatin and other statins' efficacy via their involvement in the drug activation[90], which may

explain part of the high heterogeneity observed regarding statins' effect on delirium[91]. Our results

may, thus, suggest a reconsideration of a possible role for statins in improving delirium prevention or

treatment.

Additionally, we identified proteins previously suggested as therapeutic targets for e.g. cancers

(ADAM8[94], GGH[95], PILRA[96]) and AD (PILRA[97]). This may offer promising opportunities for investigating

new delirium treatment targets. However, results should be interpreted with caution, as liberal p-

value thresholds – up to $p < 0.05$ – were used to indicate proteomic support for our druggability

assessment, and some proteins (e.g. PON3 and ADAM8) were not replicated in our replication MR,

although the same effect direction was still observed (Table 1 and Supplementary Data 1).

The main strength of our analysis is the large-scale investigation of delirium genetic and proteomic

risk factors. Both in terms of sample size, follow-up time before protein measurement and delirium

episodes, and number of genetic variants / proteins tested, this is to our knowledge the largest study

on the molecular background of delirium risk conducted so far. On the other hand, some of the

limitations of the study include the underdiagnosis of delirium in hospital health records from which

the phenotype was mostly derived[98]. This misclassification could introduce noise to the results,

limiting discovery of genetic and protein effects. Also, the small sample sizes of the non-European sub-

populations hinders the identification of risk factors specific to them. Moreover, not the full spectrum

of the human proteome is captured in the assayed plasma proteins, potentially missing proteins

important for delirium biology and prognosis. Finally, although the use of plasma proteins as predictive

biomarkers is of great significance, proteomic profiles of delirium-relevant tissues, such as brain or

CSF would be invaluable.

In conclusion, our results point out to an oligogenic genetic architecture for delirium, with the *APOE*
locus identified as a strong, potentially population specific genetic risk factor, independently of
dementia. However, further replication in larger non-European cohorts is required. Our plasma
proteome analysis supports previous findings and discovers putatively novel proteins implicated to
delirium, some of which suggested for therapeutic applications. Taken together, genetic and
proteomic risk factors suggest a shared aetiology between delirium and dementias, possibly
contributing to a better understanding of delirium's complex biological origin and the discovery of
clinically relevant biomarkers.

Methods

Study populations

The project utilises biomedical data from ancestrally diverse large-scale cohorts. Included cohorts
were either (a) databases containing individual-level genomic measurements linked to healthcare
records, or (b) previously published summary results from genomic studies on delirium phenotypes.
Contributing individual-level cohorts include the UK Biobank[99,100] (UKB) and the All of Us Research
Program[101] (AoU). Summary results have been obtained from ancestrally Finnish (FinnGen[102]; $n_{cases} =$
3,371; $n_{controls} = 388,560$) and European participants (Michigan Genomics Initiative cohort
(MGI)[103]; $n_{cases} = 160$; $n_{controls} = 44,654$).

The UKB is a population-based prospective study, containing a rich set of genetic and phenotypic data
for approximately 500,000 participants living across the United Kingdom. Participants, aged 40 to 69
years old at recruitment between 2006 – 2010, have been linked to their annually updated electronic
health records, allowing longitudinal investigation of healthcare outcomes. Similarly, AoU includes
genomic data and healthcare outcomes for approximately 245,000 individuals from diverse
populations in the USA.

Age distributions for UKB and AoU participants, along with delirium and all-cause dementia prevalence
by age group, can be found in Supplementary Figure 1. Age distributions for the FinnGen and MGI
cohort can be found in their respective original publications, that is Kurki et al. (2023; Supplementary
Methods)[102] and Zawistowski et al. (2023)[103] respectively. Age distribution of delirium first events in
FinnGen can be found here: https://r10.risteys.finregistry.fi/endpoints/F5_DELIRIUM.

Delirium phenotype

The analysis focused on delirium episodes that were not triggered by substance intoxication or

withdrawal[2]. For convenience, such delirium episodes will hereby be referred as simply delirium.

Delirium cases were defined as individuals with one or more delirium-corresponding codes in their

electronic health records (EHR), that is hospital inpatient, death register or primary care data. The

relevant codes were: "F05" (delirium, not induced by alcohol and other psychoactive substances) for

International Classification of Diseases, 10th version (ICD-10)[104] and "293.0" (Acute confusional state)

for ICD-9[105]. Read v2 and v3 codes[106] for primary care data mapping to delirium were obtained from a

previously defined list by Kuan et al (2019)[107], published in the HDRUK Phenotype Library

(https://phenotypes.healthdatagateway.org/).

Discovery of genetic risk factors

A Genome-Wide Association Study (GWAS) framework was implemented in order to identify genetic

variants associated with delirium in UKB's and AoU's ancestrally distinct sub-populations. For this

purpose, the REGENIE software (version 3.2.2) was used, which carries out a logistic regression

analysis between a disease phenotype and each genetic variant, accounting for covariates, population

structure and relatedness of participants[108].

In UKB, the set of imputed genotypes was used[99] (Data-Field 22828), filtered to include variants with

> 5 minor alleles in cases and controls, imputation score > 0.5, missingness rate < 3% and deviation

from Hardy-Weinberg Equilibrium (HWE) with p-value < 10^{-6}. Individuals were filtered to include those

with missingness rate < 5%, no mismatch between reported and genetically inferred sex (Data-Field

22001), no sex chromosome aneuploidy (Data-Field 22019), no excessive heterozygosity (Data-Field

22027) and no more than ten 3rd degree relatives (Data-Field 22021). The covariates considered for

the UKB GWAS included: age, sex, genotyping batch (Data-Field 22000) and the first 20 pre-computed

genomic principal components (data-field 22009). Here, age was defined as age at first delirium

occurrence for cases and age at last data freeze (31 October 2022) or age at death for controls. GWAS

were conducted separately for sub-populations of white British ancestry (EUR; $n_{cases} = 7,176$;

$n_{controls} = 385,097$), African (AFR; black / black British; $n_{cases} = 115$; $n_{controls} = 7,480$) and south

Asian (SAS; $n_{cases} = 107$; $n_{controls} = 9,356$) ethnic backgrounds. Summary statistics from the UKB

GWAS were converted from GRCh37 to GRCh38 genomic coordinates using the LiftOver software[109].

In total the analysis covered approximately 22.5, 13.6 and 8.8 million genetic variants in EUR, AFR, SAS

ancestries respectively.

In AoU, short read whole genome sequencing genotypes were used[101] for conducting GWAS on

European (EUR; $n_{cases} = 652$; $n_{controls} = 119,817$), African/African American (AFR; $n_{cases} = 233$;

$n_{controls} = 52,300$), and admixed American/Hispanic (AMR; $n_{cases} = 117$; $n_{controls} = 39,977$) sub-

populations. The same GWAS framework as described for UKB was followed, with the exception of

not including genotyping batch and principal components 11-20 as covariates, as they were not

available in the AoU datasets. Sub-populations with a low number of delirium cases (<20) were

excluded from the analysis. Those consisted of east Asian ethnic background in UKB and east Asian

and middle Eastern genetic ancestries in AoU.

In order to increase power to detect genetic associations, our GWAS summary statistics and previously

published GWAS results were combined into a multi-ancestry genome-wide meta-analysis. The METAL

software (version 2020-05-05)[110] was used to conduct a fixed effects inverse-variance meta-analysis

on the set of 24,951,029 variants that were present in at least two studies. The genomic control

correction method was applied in METAL to allow for multi-ancestry analysis. In total, up to 1,059,130

individuals ($n_{cases} = 11,931$; $n_{controls} = 1,047,199$) were included in the meta-analysis. Genome-

wide significance was considered at a 5×10^{-8} p-value threshold. Significantly associated variants at the

multi-ancestry meta-analysis were inspected for consistency at each contributing sub-cohort.

Descriptive statistics for each sub-cohort are presented in Supplementary Table 1.

Wherever reported, Odds Ratios (OR) were calculated as $OR = e^{\beta}$, where β is the logistic regression

coefficient. 95% Confidence Intervals (CI) for the ORs were calculated as $OR_{95\% \, CI} = e^{\beta} \pm 1.96 *$

$SE_{\beta} * e^{\beta}$.

Sensitivity analyses

A series of sensitivity analyses were conducted in addition to our main genetic analysis, to:

• identify genetic variants associated with delirium independently of *APOE*. For this purpose,

we performed a GWAS on the UKB EUR cohort conditional on the *APOE*-ε4 haplotype count

(0, 1 or 2) (Supplementary Figure 2). We inferred *APOE*-ε4 haplotypes for each participant

based on their rs429358 and rs7412 genotypes, as described in previous studies[35].

• Identify genetic signals for delirium independently of dementia. To this end, we conducted in

the UKB EUR cohort (a) delirium GWAS conditional on dementia (dementia-adjusted), by

including all-cause dementia status as covariate (Supplementary Figure 3); (b) delirium GWAS

on sub-cohorts stratified by all-cause dementia status (i.e. whether or not individuals have

developed all-cause dementia at any time point) (Supplementary Figure 4); and similarly (c)

delirium GWAS on sub-cohorts stratified by Alzheimer disease (AD) status (Supplementary

Figure 5).

•   better distinguish genetic signals in true delirium cases and controls in the elderly, by
661   conducting a delirium GWAS on UKB EUR participants aged 60 years or older (Supplementary
662   Figure 6).

For all sensitivity analyses, the same GWAS framework as in our main analysis of genetic risk factors
was followed. All sensitivity analyses were repeated in the AoU EUR cohort for replication (significance
p-value threshold < 0.05). Sample sizes for each analysis and results for rs429358, the top delirium-
associated genetic variant from our main genetic risk factor analysis, are presented in Supplementary
Table 2.

For the analyses that utilised dementia or AD status in UKB, the algorithmically defined all-cause
outcomes were used (Data-Field 42018), provided by UKB. Briefly, disease outcomes were constructed
based on self-reported medical conditions reported at the baseline assessment, ICD-9/10 codes in
hospital diagnoses and procedures, and ICD-10 codes in Death Register records. The full list of ICD
codes for all-cause dementia and AD is included in Supplementary Table 16 (as reported in UKBiobank
Recourse 460, https://biobank.ctsu.ox.ac.uk/ukb/refer.cgi?id=460). All-cause dementia and AD
diagnoses codes for the AoU cohort are reported in Supplementary Table 17.

Multi-trait analysis between delirium and Alzheimer disease

Given the close inter-relationship between delirium and AD[6], we wanted to quantify the shared
genetic architecture between the two traits. For this purpose, we used the high-definition likelihood
(HDL) software (v1.4.0)[111] to estimate the SNP heritability (h^2_{SNP}) of delirium and the genetic
correlation (r_g) between delirium and AD using GWAS summary statistics. SNP heritability, the
proportion of phenotypic variance explained by the additive SNP genetic factors[112], was estimated in
the observed scale, and converted to the liability scale using the equation: $h^2_{SNP,l} =$
$h^2_{SNP} \frac{K(1-K)}{z^2} \frac{K(1-K)}{P(1-P)}$, where K=0.015 is the population prevalence of delirium[4], P=0.018 is delirium
prevalence in UKB, and z is standard normal probability density function's height at the quantile
corresponding to cumulative probability K. The equation is derived from Lee et al (2011)[113]. Genetic
correlation is a measure of the variance shared by two traits due to genetic causes[112]. For AD, we used
the largest to-date AD GWAS meta-analysis, Bellenguez et al (2022)[58]. The AD GWAS was conducted
on 487,511 European individuals (Stage I: 39,106 clinically diagnosed AD cases and 46,828 proxy AD
cases) and 21 million variants. AD summary statistics were obtained from European Bioinformatics
Institute GWAS Catalog (https://www.ebi.ac.uk/gwas/) under accession no. GCST90027158. Delirium
summary statistics were taken from our UKB EUR GWAS sub-cohort, to better match the ancestry of
the AD GWAS summary statistics and the HDL pre-computed European-ancestry reference panel.

We also applied a joint analysis of summary statistics between delirium and AD. Such approach
increases statistical power to detect genetic associations for each trait[34]. The multi-trait analysis of
GWAS (MTAG) software (v1.0.8) was used for this purpose[34], jointly analysing summary statistics from
our delirium meta-analysis – excluding the AoU sets – and the Bellenguez et al[58] AD summary statistics.
The MTAG analysis for the discovery of delirium genetic risk variants was conducted on 9,883,704
SNPs that overlapped across the two disorders, filtered for minor allele frequency >= 0.01 and sample
size N >= (2/3) * 90th percentile for each trait. MTAG results are trait-specific summary statistics (i.e.,
effect estimates, standard errors and p-values), interpreted similarly with single-trait GWAS results.
The genome-wide significance threshold was defined as a p-value = 5×10^{-8}. Independent lead variants
were defined as the most significant variants within a ±500kb region, using the GWASLab python
package (version 3.4.46)[114].

The AoU EUR set was held out for replication of the MTAG lead hits. A multi-trait analysis with AD was
conducted on the replication set as described above. Lead variants were considered replicated if they
had a Bonferroni adjusted p-value < (0.05 / number of lead variants) and same direction of effect
across the discovery and replication set.

Mediation Analysis

We employed a mediation analysis framework in order to quantify to what extend the effect of *APOE*
gene on delirium is mediated through underlying dementia status. Mediation analysis enables the
decomposition of an exposure's total causal effect on an outcome, here *APOE* and delirium
respectively, into direct and indirect effect through a hypothesised mediator variable (here
dementia)[53]. We used the R package 'medflex'[53] (v0.6-10) to calculate the so-called natural direct and
natural indirect effects of the number of *APOE-ε4* haplotypes (0,1,2) on delirium, mediated through
dementia. When exponentiated, natural direct and indirect effect estimates can be interpreted as
odds ratios. Medflex's weighting-based approach was used, to estimate the unobserved potential
outcomes. For the natural effect model's parameters, bootstrap-based (n=1,000) standard errors and
Wald-type two-sided p-values were obtained. Sex and age were used as covariates.

Mediation analysis, as implemented under the counterfactual framework in 'medflex', relies on the
assumption that, after adjusting for baseline covariates, there is no unmeasured confounding
between (i) exposure and outcome, (ii) exposure and mediator, and (iii) mediator and outcome[53]. It is
also assumed that (iv) there are no confounders of the mediator-outcome relationship that are
themselves induced by the exposure[53]. We assessed the robustness of our mediation analysis to
violations of unmeasured confounding assumptions, using the E-value sensitivity analysis method[36,115].
An E-value, calculated as $E - value = RR + \sqrt{RR * (RR - 1)}$, where $RR \approx OR$, for $OR > 1$ is the

observed direct or indirect effect risk ratio[115], can be interpreted as the minimum unmeasured

confounder effect size required to completely explain away the observed effect[36].

We also conducted a sensitivity mediation analysis additionally adjusted for measurements of

cognitive function, socioeconomic deprivation and chronic disease burden, to assess the robustness

of our analysis to common dementia and delirium risk factors[4]. General cognitive ability was calculated

as a composite measure – i.e. the first unrotated principal component – of four UKB cognitive tests:

fluid intelligence (Data-Field 20016), numeric memory (Data-Field 4282), reaction time (Data-Field

20023, log transformed) and visual memory (Data-Field 399, log1p transformed), as described and

validated in previous studies[116,117]. When cognitive tests were unavailable at baseline, measurements

of the same tests at repeat assessments or online follow-up were used if available. The Townsend

deprivation index immediately before joining UKB (Data-Field: 22189, decile transformed) was used

as a measure of socioeconomic deprivation[118]. The Charlson Comorbidity Index (CCI) was calculated

as an estimate of chronic disease burden[119]. CCI is a weighted sum of 12 chronic comorbid diseases,

here calculated at the time of delirium episode. Diseases were extracted from self-reported medical

conditions and cancers (Data-Fields: 20002 and 20001), and ICD-9 and ICD-10 disease codes[120] from

linked healthcare records. Weights were obtained from Quan et al[119]. This sensitivity analysis was

conducted on a subset of n = 141,864 individuals, due to missing cognitive function data.

Proteomic study population

Plasma proteome data were available in UKB for a subset of 53,075 participants. Protein

measurements of 2,923 unique plasma proteins[121] were derived from blood samples taken during

randomly selected participants' initial UKB assessment visit between 2006-2010. Proteins were

measured using the antibody-based Olink Explore 3072 proximity extension assay. Proteome data

have been previously undergone extensive quality control[121]. As additional filtering in the present

analysis, European participants from batches 0 to 6 were extracted, as they have been reported to be

highly representative of the UKB European population[121]. Moreover, protein measurements with

>20% missing data were removed and the remaining proteins were mean-imputed, inverse-rank

normalised and standardised (mean zero standard deviation 1) to ensure homogeneity across the

proteins. Delirium incident cases were defined as the participants whose first reported delirium

episode was > 1 years after baseline, that is, the date of blood sample collection at the first UKB

assessment visit (Data-Field 53-0.0). Delirium data were available for up to 16 years of follow-up after

baseline (censoring date: 31 October 2022). The final population consisted of 32,652 European

participants and 2,919 plasma proteins. 541 participants had an incident delirium diagnosis within the

follow-up period (cases). Of the remaining 32,111 participants (controls), 29,440 reached the end of

follow-up without a delirium diagnosis, and 2,671 died before the end of follow-up. Follow-up
information was available for all participants.

Discovery of protein risk factors

To explore the relationships between baseline protein levels and incident delirium, we performed a
proteome-wide association study (PWAS) on the UKB proteomic study population. Multivariable
logistic regression models were fit between each protein as predictor and incident delirium status as
outcome. In total, 2,919 models were fit, equal to the number of proteins. The models were adjusted
for sex, Body Mass Index (BMI) and age at baseline. Associations were deemed significant at a
Bonferroni adjusted p-value threshold: p-value < 1.7x10^{-5}. For sensitivity analyses, we further adjusted
protein models for *APOE*-ε4 haplotype status – zero, one or two copies of the haplotype – and for
interaction between each protein and *APOE*-ε4.

We performed a pathway enrichment analysis on the set of Bonferroni-adjusted significant proteins
emerging from the protein-wide association analysis. We used the Enrichr[122] web-based tool and
pathway annotations based on the Reactome[123], Molecular Signatures Database (MSigDB)[124] and
Kyoto Encyclopedia of Genes and Genomes (KEGG)[125] databases. The full set of Olink proteins was
used as background genes. Fisher's exacts tests were implemented to assess whether the identified
proteins significantly overlap with the proteins in any of the pathways. Q-values were obtained by
adjusting p-values for multiple testing using the Benjamini-Hochberg method.

Protein selection and prediction models

To investigate whether baseline plasma proteome can improve prediction of incident delirium, a
supervised machine learning approach was implemented. The LASSO (Least Absolute Shrinkage and
Selection Operator) method[37] was utilised for the selection of important proteins and to avoid
overfitting given the high multicollinearity of proteomics data. For this analysis, the full set was
randomly split into a training (80%; $n_{cases} = 436$; $n_{controls} = 25,733$) and test (20%; $n_{cases} =$
105; $n_{controls} = 6,378$) set. A LASSO model for binary outcomes was implemented in the training set
using the glmnet R package (version 4.1.8)[126]. Here, the whole set of 2,919 proteins adjusted for
demographic covariates: age, sex and BMI were used as predictors of incident delirium. In brief, the
coefficients penalty parameter lambda was tuned using a 10-fold Cross-Validation (CV) framework for
100 lambdas between 10^{-6} and 0.07. The model with lambda.1se was chosen as the most
parsimonious, giving the strictest model such that cross-validated error is within one standard error
of the minimum[126]. To increase the robustness of the LASSO protein selection, a stability selection[38]
approach was additionally applied. For each of 100 random subsampling iterations of the training set,
including all 436 delirium cases and an equal number of 436 randomly selected controls, a LASSO

model as described above was fit using the penalty factor tuned in the full training set. The proteins

that were selected on at least half of the subsampling iterations were chosen as robustly selected

(stability-selected proteins).

Four logistic regression models with incident delirium as outcome were subsequently re-fit in the

training set: (a) using only demographic covariates (age, sex and BMI) as predictors (basic model); (b)

using only the stability selected proteins as predictors (proteomic model); (c) using both demographic

covariates and the stability selected proteins as predictors (proteomic + basic model); and (d) using

demographics, stability selected proteins and *APOE*-ε4 haplotype status as predictors (*APOE* +

proteomic + basic model). For the models that included proteins as predictors (b,c and d), stepwise

regression models were fit, starting with all the stability-selected proteins and removing predictors

until no AIC improvement was observed.

The performance of the models was evaluated in the held-out test set. Receiver operating

characteristic (ROC) curves, Area Under the ROC Curve (AUC) and Precision – Recall curves and AUC

(PR-AUC) estimates were used to compare the predictive performance of the three models in the test

set. Precision – Recall metrics were chosen as they are more sensitive to binary outcome imbalance[127],

as is the situation here. Two-sided Delong tests were used to compare whether AUCs were

significantly different between each model pair[128] (ΔAUC p-value < 0.05).

pQTL analysis

We obtained protein quantitative trait loci (pQTL), that is genetic variants affecting plasma protein

levels, from the UKB proteomic study population. A GWAS was conducted for each of the 2,923

inverse-rank normalised and standardised protein traits. Autosomal and X chromosome genetic

variants were derived from UKB's called genotypes (Data-Field 22418), filtered to include variants with

missingness < 1%, HWE deviation p-value > 10^{-15}, minor allele frequency > 1%. The proteomic study

population was further filtered to include unrelated, up to 2nd degree, individuals, with missingness

rate < 10%. The GWAS on each protein, were conducted using REGENIE (version 3.2.2)[108] on 30,272

individuals and ~540,000 genetic variants. Age, age^2, sex, sex*age, and sex*age^2, batch, UKB

assessment centre, UKB genetic array, time between blood sampling and measurement, and the first

20 genetic principal components were used as covariates.

2,464 proteins were significantly associated with at least one genetic variant (p < $5x10^{-8}$). Per protein,

independent pQTLs were obtained through linkage disequilibrium (LD)-based clumping, including

variants with LD r^2 < 0.2 within ±250 kb windows of the top associated pQTLs. Genotype filtering and

LD-clumping was performed using PLINK (v1.90b)[129].

The independent pQTLs derived here were used as genetic instruments for protein levels in the

subsequent mendelian randomisation and colocalisation analyses.

Mendelian randomisation

Mendelian randomisation (MR) is a method used to assess potential causal influence of a modifiable

exposure on an outcome, often disease risk. MR analyses are based on the use of genetic variants as

instrumental variables (IV). IVs are variables associated with an exposure but not with the outcome of

interest through any other pathway[130,131]. Three assumptions are required for MR to be valid: (1) IVs

are significantly associated with the exposure; (2) there are no confounders of the IVs and the

outcome; and (3) IVs do not affect the outcome other than through the exposure (no pleiotropy)[130].

We assessed whether the identified protein risk factors (exposures) showed causal effects on delirium

(outcome), using a two-sample MR approach[132]. Genetic instruments for protein exposure traits

comprised of the per-protein independent pQTLs, as derived from our pQTL analysis in UKB (p-value

$< 5\text{x}10^{-8}$, LD $r^2 < 0.2$). To further ensure no weak instrument bias in our genetic instrument pQTLs -

relevant to MR assumption (1) - we also excluded pQTLs with an F-statistic < 10 in their per-protein

exposure GWAS. F-statistics were approximated as $F = \frac{\widehat{\gamma_j^2}}{\sigma_j^2}$ for each pQTL j, where $\hat{\gamma}$ is the pQTL-

exposure effect size and σ its respective standard error[133]. To minimise chances of including genetic

instruments with pleiotropic effects, we included only (a) pQTLs associated with less than 5 proteins

(p-value $< 5\text{x}10^{-8}$), and (b) cis-pQTLs, that is pQTLs in close proximity with their associated protein's

encoding gene. cis-pQTLs were defined as being located within ±1Mb (10^6 base pairs) of the protein-

encoding gene's coding region. Protein-encoding genes' start and end positions were derived as

reported in the metadata from Sun et al[121]. Genetic associations of the pQTLs with delirium were

derived from our UKB-EUR GWAS excluding the individuals in the proteomic set, to avoid sample

overlap in our two-sample setting ($n_{cases} = 6{,}650$; $n_{controls} = 354{,}251$). The same procedure as our

full UKB-EUR GWAS was followed, as described in the section 'Discovery of genetic risk factors'.

For our main MR analysis, 1989 proteins were tested in total. The inverse variance weighted (IVW)

method was used[134] to assess causal estimates between 1,738 proteins with > 1 cis-pQTLs and

delirium. For 251 proteins with 1 cis-pQTLs the Wald ratio method was used. We further employed

the weighted median (WM), maximum likelihood and MR-Egger sensitivity MR methods[135], to test for

consistency of estimates with our main analysis. The MR-Egger intercept and the Cochran's Q tests

were used to assess for the presence of horizontal pleiotropy and heterogeneity in the IVs

respectively[136–138]. MR associations were considered significant at an FDR q < 0.05 in our main IVW or

Wald ratio MR analysis. For significant proteins, IVW or Wald ratio MR were repeated using delirium

in the dementia-free UKB sub-cohort as outcome GWAS, again using an FDR q threshold of 0.05.

Finally, the FinnGen delirium GWAS was used as a replication MR outcome set, following the same MR

framework as described above. A significance threshold of p-value < 0.05 was used in the replication

MR. Full MR results are reported in Supplementary Table 12 and 13. All MR analyses were conducted

using the TwoSampleMR R package (version 0.5.11)[135]. A full list of the cis-pQTLs used, together with

their association statistics with each exposure and delirium is available in Supplementary Data 3. A

STROBE-MR checklist[131] for the conducted MR analyses can be found in the Supplementary Table 18.

Colocalisation

We tested whether genetic signals for delirium and each of the plasma proteins colocalise, i.e. the two

traits are affected by the same, rather than distinct genetic variants in a specific genomic region[40]. For

each of the 2,456 proteins with at least 1 pQTL, we analysed genomic regions around lead pQTLs with

boundaries defined by recombination hotspot locations, based on a previously published map[139]

(https://bitbucket.org/nygcresearch/ldetect-data/src/master/EUR). We used the coloc R package

(v5.2.3)[39], specifically the Approximate Bayes Factor colocalisation method (coloc.abf), which assumes

at most one causal variant per trait per region[39]. Using per-trait GWAS results and the default prior

probabilities of $p1 = p2 = 10^{-4}$ for each variant being the causal for delirium or the analysed protein

respectively, and $p12 = 10^{-5}$ for each variant being the causal for both, coloc.abf calculates per-

variant posterior probabilities that the two traits have a common causal genetic variant in a genomic

region (PP.H4 as per coloc notation). Proteins and delirium were considered to share a causal genetic

variant when PP.H4 > 0.9. Suggestive colocalisation was considered for protein-delirium pairs with

PP.H4 > 0.5.

Druggability assessment

We further investigated whether selected delirium-associated proteins are suitable to act as potential

drug targets. The selected proteins included those identified as significant in both our protein risk

factor (p < 0.05) and MR analyses (FDR q < 0.05), as well as having a consistent direction of effect in

the two analyses. We utilised the "druggable genome" resource developed by Finan et al (2017)[41]. In

this resource 4,479 genes encoding drugged or druggable proteins were systematically identified, and

further stratified into 3 tiers based on druggability evidence strength; as described by Finan et al: "Tier

1 (1427 genes) included efficacy targets of approved small molecules and biotherapeutic drugs as well

as clinical-phase drug candidates. Tier 2 was composed of 682 genes encoding targets with known

bioactive drug-like small-molecule binding partners as well as those with ≥50% identity (over ≥75% of

the sequence) with approved drug targets. Tier 3 contained 2370 genes encoding secreted or

extracellular proteins, proteins with more distant similarity to approved drug targets, and members

of key druggable gene families not already included in tier 1 or 2."[41] We therefore tested whether our
selected proteins overlap the with druggable genes' encoding proteins. For proteins in Tier 1
druggability we searched the Drug Bank (https://www.drugbank.ca/) and https://clinicaltrials.gov/
databases for additional information on drug indications and clinical trial status respectively. The
druggable genome can be found in the Supplementary Table 1 of the original Finan et al publication[41].

KGWAS

We implemented Knowledge Graph GWAS (KGWAS), a novel geometric deep learning approach that
integrates GWAS summary statistics with functional genomics data (variant and gene-level
annotations and interactions), to improve power in GWAS association testing[42]. Using functional
genomics knowledge graphs, KGWAS estimates variants' prior relevance to disease and recomputes
the original GWAS associations in a p-value weighting framework. We used our delirium GWAMA
summary statistics and KGWAS's default fast mode, which uses Enformer embedding for variant
feature and ESM embedding for gene features. We further used MAGMA[140], as integrated in KGWAS,
for gene prioritisation of KGWAS significant associations. We used a p-value threshold of 0.05 / 16,637
$= 3\times10^{-6}$ for gene-based p-values estimated by MAGMA, 16,637 being the number of genes tested.

Acknowledgments

This work used the Edinburgh Compute and Data Facility (ECDF) (http://www.ecdf.ed.ac.uk/).

This research has been conducted using the UK Biobank Resource projects 788 and 44986. This work
uses data provided by patients and collected by the NHS as part of their care and support.

UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as
a Research Tissue Bank (RTB) approval.

We gratefully acknowledge *All of Us* participants for their contributions, without whom this research
would not have been possible. We also thank the National Institutes of Health's *All of Us* Research
Programme for making available the participant data examined in this study.

We want to acknowledge the participants and investigators of the *FinnGen* study.

The authors acknowledge the Michigan Genomics Initiative participants, Precision Health at the
University of Michigan, the University of Michigan Medical School Central Biorepository, and the
University of Michigan Advanced Genomics Core for providing data and specimen storage,
management, processing, and distribution services, and the Center for Statistical Genetics in the

Department of Biostatistics at the School of Public Health for genotype data curation, imputation, and management in support of the research reported in this publication.

This research was funded by the *Legal & General Group* (research grant to establish the independent Advanced Care Research Centre at University of Edinburgh). The funder had no role in conduct of the study, interpretation or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of Legal & General.

Data availability

Details for accessing individual-level data can be found here:

- for UK Biobank https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access
- for All of Us Research Programme https://www.researchallofus.org/register

Details on obtaining delirium GWAS summary statistics used in this work can be found here:

- for FinnGen R10 release https://www.finngen.fi/en/access_results
- for MGI freeze 3 https://precisionhealth.umich.edu/our-research/michigangenomics

GWAS summary statistics generated in this work will be made publicly available via University of Edinburgh's Datashare service [DOI to be released upon publication]. Summary statistics for the proteomic, mendelian randomisation and colocalisation analyses can be found in the Supplementary Tables file and Supplementary Data 2 and 3.

Code availability

All software used in the present study is publicly available. The code used for all analyses in the study can be found on GitHub: https://github.com/VasiliosRaptis/deliriumGen.

References

1.   Anand, A. & MacLullich, Alasdair. M. J. Delirium in older adults. *Medicine* **49**, 26–31 (2021).

2.   American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*.
(American Psychiatric Association, 2013). doi:10.1176/appi.books.9780890425596.

3.   Wilson, J. E. *et al.* Delirium. *Nat Rev Dis Primers* **6**, 90 (2020).

4.   Inouye, S. K., Westendorp, R. G. & Saczynski, J. S. Delirium in elderly people. *The Lancet* **383**,
911–922 (2014).

5.   Gordon, E. H., Ward, D. D., Xiong, H., Berkovsky, S. & Hubbard, R. E. Delirium and incident
dementia in hospital patients in New South Wales, Australia: retrospective cohort study. *BMJ*
e077634 (2024) doi:10.1136/bmj-2023-077634.

6.   Fong, T. G. & Inouye, S. K. The inter-relationship between delirium and dementia: the
importance of delirium prevention. *Nat Rev Neurol* **18**, 579–596 (2022).

7.   Watne, L. O. *et al.* Cerebrospinal fluid quinolinic acid is strongly associated with delirium and
mortality in hip-fracture patients. *Journal of Clinical Investigation* **133**, e163472 (2023).

8.   Tsui, A. *et al.* Persistent delirium is associated with cerebrospinal fluid markers of neuronal
injury. *Brain Communications* **6**, fcae319 (2024).

9.   Krogseth, M. *et al.* Delirium, neurofilament light chain, and progressive cognitive
impairment: analysis of a prospective Norwegian population-based cohort. *The Lancet Healthy*
Longevity **4**, e399–e408 (2023).

10.   Heneka, M. T. *et al.* Neuroinflammation in Alzheimer disease. *Nat Rev Immunol* (2024)
doi:10.1038/s41577-024-01104-7.

11.   Leslie, D. L. & Inouye, S. K. The Importance of Delirium: Economic and Societal Costs. *J*
American Geriatrics Society **59**, (2011).

12.   Sepulveda, E. *et al.* The complex interaction of genetics and delirium: a systematic review
and meta-analysis. *Eur Arch Psychiatry Clin Neurosci* **271**, 929–939 (2021).

13.   Massimo, L. *et al.* Genetic and environmental factors associated with delirium severity in
older adults with dementia. *Int J Geriat Psychiatry* **32**, 574–581 (2017).

14.   Van Munster, B. C. *et al.* Genetic polymorphisms in the DRD2, DRD3, and SLC6A3 gene in
elderly patients with delirium. *American J of Med Genetics Pt B* **153B**, 38–45 (2010).

15.   Ely, W. E. *et al.* Apolipoprotein E4 polymorphism as a genetic predisposition to delirium in
critically ill patients: *Critical Care Medicine* **35**, 112–117 (2007).

16.   Kim, J. *et al.* Antipsychotics and dopamine transporter gene polymorphisms in delirium
patients. *Psychiatry Clin Neurosci* **59**, 183–188 (2005).

17.   Van Munster, B. C., Korevaar, J. C., De Rooij, S. E., Levi, M. & Zwinderman, A. H. The
association between delirium and the apolipoprotein E ε4 allele in the elderly. *Psychiatric Genetics*
17, 261–266 (2007).

18.   Van Munster, B. C., Zwinderman, A. H. & De Rooij, S. E. Genetic Variations in the Interleukin-
6 and Interleukin-8 Genes and the Interleukin-6 Receptor Gene in Delirium. *Rejuvenation Research*
14, 425–428 (2011).

19. Leung, J. M. *et al.* Apolipoprotein E e4 Allele Increases the Risk of Early Postoperative
Delirium in Older Patients Undergoing Noncardiac Surgery. *Anesthesiology* **107**, 406–411 (2007).

20. Cunningham, E. L. *et al.* Observational cohort study examining apolipoprotein E status and
preoperative neuropsychological performance as predictors of post-operative delirium in an older
elective arthroplasty population. *Age and Ageing* **46**, 779–786 (2017).

21. Van Munster, B. C., Korevaar, J. C., Zwinderman, A. H., Leeflang, M. M. & De Rooij, S. E. J. A.
The Association Between Delirium and the Apolipoprotein E Epsilon 4 Allele: New Study Results and
a Meta-Analysis. *The American Journal of Geriatric Psychiatry* **17**, 856–862 (2009).

22. Terrelonge, M. *et al.* KIBRA, MTNR1B, and FKBP5 genotypes are associated with decreased
odds of incident delirium in elderly post-surgical patients. *Sci Rep* **12**, 556 (2022).

23. Adamis, D., Meagher, D., Williams, J., Mulligan, O. & McCarthy, G. A systematic review and
meta-analysis of the association between the apolipoprotein E genotype and delirium. *Psychiatric*
Genetics **26**, 53–59 (2016).

24. Visscher, P. M. *et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation. *The*
American Journal of Human Genetics **101**, 5–22 (2017).

25. Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson's
disease. *The Lancet Neurology* **19**, 170–178 (2020).

26. Orme, T., Guerreiro, R. & Bras, J. The Genetics of Dementia with Lewy Bodies: Current
Understanding and Future Directions. *Curr Neurol Neurosci Rep* **18**, 67 (2018).

27. Andrews, S. J. *et al.* The complex genetic architecture of Alzheimer's disease: novel insights
and future directions. *eBioMedicine* **90**, 104511 (2023).

28. McCoy, T. H., Hart, K., Pellegrini, A. & Perlis, R. H. Genome-wide association identifies a
novel locus for delirium risk. *Neurobiology of Aging* **68**, 160.e9-160.e14 (2018).

29. Heinrich, M. *et al.* Association between genetic variants of the cholinergic system and
postoperative delirium and cognitive dysfunction in elderly patients. *BMC Med Genomics* **14**, 248
(2021).

30. Westphal, S. *et al.* Genome-wide association study of myocardial infarction, atrial fibrillation,
acute stroke, acute kidney injury and delirium after cardiac surgery – a sub-analysis of the RIPHeart-
Study. *BMC Cardiovasc Disord* **19**, 26 (2019).

31. Wiredu, K., Aduse-Poku, E., Shaefi, S. & Gerber, S. A. Proteomics for the Discovery of Clinical
Delirium Biomarkers: A Systematic Review of Major Studies. *Anesthesia & Analgesia* **136**, 422–432
(2023).

32. Mosharaf, M. P., Alam, K., Gow, J. & Mahumud, R. A. Cytokines and inflammatory
biomarkers and their association with post-operative delirium: a meta-analysis and systematic
review. *Sci Rep* **15**, 7830 (2025).

33. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*
562, 203–209 (2018).

34. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics using
MTAG. *Nat Genet* **50**, 229–237 (2018).

35.   Lumsden, A. L., Mulugeta, A., Zhou, A. & Hyppönen, E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. *eBioMedicine* **59**, 102954 (2020).

36.   Smith, L. H. & VanderWeele, T. J. Mediational E-values: Approximate Sensitivity Analysis for Unmeasured Mediator-Outcome Confounding. *Epidemiology* **30**, 835–837 (2019).

37.   Tibshirani, R. Regression Shrinkage and Selection Via the Lasso. *Journal of the Royal Statistical Society Series B: Statistical Methodology* **58**, 267–288 (1996).

38.   Meinshausen, N. & Bühlmann, P. Stability Selection. *Journal of the Royal Statistical Society Series B: Statistical Methodology* **72**, 417–473 (2010).

39.   Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *PLoS Genet* **10**, e1004383 (2014).

40.   Zuber, V. *et al.* Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. *The American Journal of Human Genetics* **109**, 767–782 (2022).

41.   Finan, C. *et al.* The druggable genome and support for target identification and validation in drug development. *Sci. Transl. Med.* **9**, eaag1166 (2017).

42.   Huang, K. *et al.* Small-cohort GWAS discovery with AI over massive functional genomics knowledge graph. Preprint at https://doi.org/10.1101/2024.12.03.24318375 (2024).

43.   Raulin, A.-C. *et al.* ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. *Mol Neurodegeneration* **17**, 72 (2022).

44.   Bowman, K. *et al.* Vitamin D levels and risk of delirium: A mendelian randomization study in the UK Biobank. *Neurology* **92**, (2019).

45.   Xie, W. *et al.* CEND1 deficiency induces mitochondrial dysfunction and cognitive impairment in Alzheimer's disease. *Cell Death Differ* **29**, 2417–2428 (2022).

46.   Manavalan, A. *et al.* Brain site-specific proteome changes in aging-related dementia. *Exp Mol Med* **45**, e39–e39 (2013).

47.   Schmukler, E. *et al.* Altered mitochondrial dynamics and function in APOE4-expressing astrocytes. *Cell Death Dis* **11**, 578 (2020).

48.   Farrer, L. A. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis. *JAMA* **278**, 1349 (1997).

49.   Belloy, M. E. *et al. APOE* Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. *JAMA Neurol* **80**, 1284 (2023).

50.   Griswold, A. J. *et al.* Increased *APOE* ε4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds. *Alzheimer's & Dementia* **17**, 1179–1188 (2021).

51.   Bellou, E. *et al.* Age-dependent effect of APOE and polygenic component on Alzheimer's disease. *Neurobiology of Aging* **93**, 69–77 (2020).

52. Bonham, L. W. *et al.* Age-dependent effects of *APOE* ε4 in preclinical Alzheimer's disease.
Ann Clin Transl Neurol **3**, 668–677 (2016).

53. Steen, J., Loeys, T., Moerkerke, B. & Vansteelandt, S. **medflex** : An *R* Package for Flexible
Mediation Analysis using Natural Effect Models. *J. Stat. Soft.* **76**, (2017).

54. Leighton, S. P. *et al.* Delirium and the risk of developing dementia: a cohort study of 12 949
patients. *J Neurol Neurosurg Psychiatry* **93**, 822–827 (2022).

55. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2024 report of the Lancet
standing Commission. *The Lancet* **404**, 572–628 (2024).

56. Edwards, D., Handsley, M. & Pennington, C. The ADAM metalloproteinases. *Molecular*
Aspects of Medicine **29**, 258–289 (2008).

57. Lambrecht, B. N., Vanderkerken, M. & Hammad, H. The emerging role of ADAM
metalloproteinases in immunity. *Nat Rev Immunol* **18**, 745–758 (2018).

58. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related
dementias. *Nat Genet* **54**, 412–436 (2022).

59. Mattiola, I. *et al.* The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell–
mediated resistance to metastasis. *Nat Immunol* **20**, 1012–1022 (2019).

60. Chen, J., Zhao, X., Huang, C. & Lin, J. Novel insights into molecular signatures and pathogenic
cell populations shared by systemic lupus erythematosus and vascular dementia. *Funct Integr*
Genomics **23**, 337 (2023).

61. Saha, O. *et al.* The Alzheimer's disease risk gene BIN1 regulates activity-dependent gene
expression in human-induced glutamatergic neurons. *Mol Psychiatry* (2024) doi:10.1038/s41380-
024-02502-y.

62. Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M. & Buckley, N. J. Clusterin in
Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. *Front. Neurosci.*
13, 164 (2019).

63. Poljak, A. *et al.* Quantitative proteomics of delirium cerebrospinal fluid. *Transl Psychiatry* **4**,
e477–e477 (2014).

64. Zhu, X.-C. *et al.* CR1 in Alzheimer's Disease. *Mol Neurobiol* **51**, 753–765 (2015).

65. Roses, A. *et al.* Understanding the genetics of *APOE* and *TOMM40* and role of mitochondrial
structure and function in clinical pharmacology of Alzheimer's disease. *Alzheimer's & Dementia*
12, 687–694 (2016).

66. Zhu, Z. *et al.* TOMM40 and APOE variants synergistically increase the risk of Alzheimer's
disease in a Chinese population. *Aging Clin Exp Res* **33**, 1667–1675 (2021).

67. Fong, T. G. *et al.* Biomarkers of neurodegeneration and neural injury as potential predictors
for delirium. *Int J Geriat Psychiatry* **39**, e6044 (2024).

68. Fong, T. G. *et al.* Association of Plasma Neurofilament Light with Postoperative Delirium.
Annals of Neurology **88**, 984–994 (2020).

69.   Van Munster, B. C. *et al.* Neuroinflammation in Delirium: A Postmortem Case-Control Study.
Rejuvenation Research **14**, 615–622 (2011).

70.   Miao, Y., Wang, M., Cai, X., Zhu, Q. & Mao, L. Leucine rich alpha-2-glycoprotein 1 (Lrg1)
silencing protects against sepsis-mediated brain injury by inhibiting transforming growth factor
beta1 (TGFβ1)/SMAD signaling pathway. *Bioengineered* **13**, 7316–7327 (2022).

71.   Oren, R. L. *et al.* Age-dependent differences and similarities in the plasma proteomic
signature of postoperative delirium. *Sci Rep* **13**, 7431 (2023).

72.   Vasunilashorn, S. M., Dillon, S. T., Marcantonio, E. R. & Libermann, T. A. Application of
Multiple Omics to Understand Postoperative Delirium Pathophysiology in Humans. *Gerontology* **69**,
1369–1384 (2023).

73.   Peters Van Ton, A. M., Verbeek, M. M., Alkema, W., Pickkers, P. & Abdo, W. F.
Downregulation of synapse-associated protein expression and loss of homeostatic microglial control
in cerebrospinal fluid of infectious patients with delirium and patients with Alzheimer's disease.
Brain, Behavior, and Immunity **89**, 656–667 (2020).

74.   Jujić, A. *et al.* Low Levels of Selenoprotein P Are Associated With Cognitive Impairment in
Patients Hospitalized for Heart Failure. *Journal of Cardiac Failure* S1071916424000393 (2024)
doi:10.1016/j.cardfail.2024.01.010.

75.   Berasain, C. & Avila, M. A. Amphiregulin. *Seminars in Cell & Developmental Biology* **28**, 31–
41 (2014).

76.   Hong, Y. *et al.* Sepsis-associated encephalopathy: From pathophysiology to clinical
management. *International Immunopharmacology* **124**, 110800 (2023).

77.   Zaiss, D. M. W., Gause, W. C., Osborne, L. C. & Artis, D. Emerging Functions of Amphiregulin
in Orchestrating Immunity, Inflammation, and Tissue Repair. *Immunity* **42**, 216–226 (2015).

78.   Hassan, R. *et al.* Mesothelin-targeting T cell receptor fusion construct cell therapy in
refractory solid tumors: phase 1/2 trial interim results. *Nat Med* **29**, 2099–2109 (2023).

79.   Lawlor, P. G. & Bush, S. H. Delirium in patients with cancer: assessment, impact, mechanisms
and management. *Nat Rev Clin Oncol* **12**, 77–92 (2015).

80.   Amgarth-Duff, I., Hosie, A., Caplan, G. & Agar, M. A systematic review of the overlap of fluid
biomarkers in delirium and advanced cancer-related syndromes. *BMC Psychiatry* **20**, 182 (2020).

81.   Tzioras, M., Davies, C., Newman, A., Jackson, R. & Spires-Jones, T. Invited Review: APOE at
the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer's
disease. *Neuropathology Appl Neurobio* **45**, 327–346 (2019).

82.   Reas, E. T. *et al.* APOE ε4-related blood–brain barrier breakdown is associated with
microstructural abnormalities. *Alzheimer's & Dementia* **20**, 8615–8624 (2024).

83.   Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer's disease: advances in genetics,
pathophysiology, and therapeutic approaches. *The Lancet Neurology* **20**, 68–80 (2021).

84.   Yang, S.-T. *et al.* Accumulation of amyloid in cognitive impairment after mild traumatic brain
injury. *Journal of the Neurological Sciences* **349**, 99–104 (2015).

85.   Koizumi, K. *et al.* Apoε4 disrupts neurovascular regulation and undermines white matter
integrity and cognitive function. *Nat Commun* **9**, 3816 (2018).

86.   VanDusen, K. W. *et al.* The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce
Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction. *Journal of Alzheimer's*
Disease **75**, 1319–1328 (2020).

87.   Nelson, M. R. *et al.* The support of human genetic evidence for approved drug indications.
Nat Genet **47**, 856–860 (2015).

88.   Minikel, E. V., Painter, J. L., Dong, C. C. & Nelson, M. R. Refining the impact of genetic
evidence on clinical success. *Nature* **629**, 624–629 (2024).

89.   Reay, W. R. & Cairns, M. J. Advancing the use of genome-wide association studies for drug
repurposing. *Nat Rev Genet* **22**, 658–671 (2021).

90.   Draganov, D. I., Stetson, P. L., Watson, C. E., Billecke, S. S. & La Du, B. N. Rabbit Serum
Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density
Lipoprotein against Oxidation. *Journal of Biological Chemistry* **275**, 33435–33442 (2000).

91.   Chang, Y.-H. *et al.* Statin Use and Delirium Risk: An Updated Systematic Review and Meta-
Analysis. *American Journal of Therapeutics* **30**, e326–e335 (2023).

92.   Camps, J., Marsillach, J. & Joven, J. The paraoxonases: role in human diseases and
methodological difficulties in measurement. *Critical Reviews in Clinical Laboratory Sciences* **46**, 83–
106 (2009).

93.   Grdic Rajkovic, M., Rumora, L. & Barisic, K. The paraoxonase 1, 2 and 3 in humans. *Biochem*
Med 122–130 (2011) doi:10.11613/BM.2011.020.

94.   Schlomann, U. *et al.* ADAM8 as a drug target in pancreatic cancer. *Nat Commun* **6**, 6175
(2015).

95.   Shubbar, E. *et al.* High levels of γ-glutamyl hydrolase (GGH) are associated with poor
prognosis and unfavorable clinical outcomes in invasive breast cancer. *BMC Cancer* **13**, 47 (2013).

96.   Li, Q., Yang, Z., He, X. & Yang, X. Comprehensive analysis of PILRA's association with the
prognosis, tumor immune infiltration, and immunotherapy in pan-cancer. *Sci Rep* **13**, 14334 (2023).

97.   Monroe, K. *et al.* PILRA regulates microglial neuroinflammation and lipid metabolism as a
candidate therapeutic target for Alzheimer's disease. Preprint at https://doi.org/10.21203/rs.3.rs-
3954863/v1 (2024).

98.   Ibitoye, T. *et al.* Delirium is under-reported in discharge summaries and in hospital
administrative systems: a systematic review. *Delirium* (2023) doi:10.56392/001c.74541.

99.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*
562, 203–209 (2018).

100.   Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide
Range of Complex Diseases of Middle and Old Age. *PLoS Med* **12**, e1001779 (2015).

101.   The All of Us Research Program Genomics Investigators *et al.* Genomic data in the All of Us
Research Program. *Nature* **627**, 340–346 (2024).

102.   Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
population. *Nature* **613**, 508–518 (2023).

103.   Zawistowski, M. *et al.* The Michigan Genomics Initiative: A biobank linking genotypes and
electronic clinical records in Michigan Medicine patients. *Cell Genomics* **3**, 100257 (2023).

104.   World Health Organization. ICD-10 : international statistical classification of diseases and
related health problems : tenth revision. *ICD-10* (2004).

105.   World Health Organization. International classification of diseases : [9th] ninth revision,
basic tabulation list with alphabetic index. *ICD-9 : basic tabulation list with alphabetic index* (1978).

106.   Stuart-Buttle, C. D., Read, J. D., Sanderson, H. F. & Sutton, Y. M. A language of health in
action: Read Codes, classifications and groupings. *Proc AMIA Annu Fall Symp* 75–79 (1996).

107.   Kuan, V. *et al.* A chronological map of 308 physical and mental health conditions from 4
million individuals in the English National Health Service. *The Lancet Digital Health* **1**, e63–e77
(2019).

108.   Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and
binary traits. *Nat Genet* **53**, 1097–1103 (2021).

109.   Kent, W. J., Baertsch, R., Hinrichs, A., Miller, W. & Haussler, D. Evolution's cauldron:
Duplication, deletion, and rearrangement in the mouse and human genomes. *Proc. Natl. Acad. Sci.*
U.S.A. **100**, 11484–11489 (2003).

110.   Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
association scans. *Bioinformatics* **26**, 2190–2191 (2010).

111.   Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic correlations
across human complex traits. *Nat Genet* **52**, 859–864 (2020).

112.   Falconer, D. S. & Mackay, T. *Introduction to Quantitative Genetics*. (Pearson, Prentice Hall,
Harlow, 2009).

113.   Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating Missing Heritability for
Disease from Genome-wide Association Studies. *The American Journal of Human Genetics* **88**, 294–
305 (2011).

114.   He, Y., Koido, M., Shimmori, Y. & Kamatani, Y. GWASLab: a Python package for processing
and visualizing GWAS summary statistics. Preprint at https://doi.org/10.51094/jxiv.370 (2023).

115.   VanderWeele, T. J. & Ding, P. Sensitivity Analysis in Observational Research: Introducing the
E-Value. *Ann Intern Med* **167**, 268–274 (2017).

116.   Lyall, D. M. *et al.* Cognitive Test Scores in UK Biobank: Data Reduction in 480,416
Participants and Longitudinal Stability in 20,346 Participants. *PLoS ONE* **11**, e0154222 (2016).

117.   Fawns-Ritchie, C. & Deary, I. J. Reliability and validity of the UK Biobank cognitive tests. *PLoS*
ONE **15**, e0231627 (2020).

118.   Townsend, P. Deprivation. *J. Soc. Pol.* **16**, 125–146 (1987).

119.   Quan, H. *et al.* Updating and Validating the Charlson Comorbidity Index and Score for Risk
Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries. *American Journal of*
Epidemiology **173**, 676–682 (2011).

120.   Quan, H. *et al.* Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10
Administrative Data. *Medical Care* **43**, 1130–1139 (2005).

121.   Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK Biobank.
Nature **622**, 329–338 (2023).

122.   Chen, E. Y. *et al.* Enrichr: interactive and collaborative HTML5 gene list enrichment analysis
tool. *BMC Bioinformatics* **14**, 128 (2013).

123.   Milacic, M. *et al.* The Reactome Pathway Knowledgebase 2024. *Nucleic Acids Research* **52**,
D672–D678 (2024).

124.   Liberzon, A. *et al.* The Molecular Signatures Database Hallmark Gene Set Collection. *Cell*
Systems **1**, 417–425 (2015).

125.   Kanehisa, M. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Research* **28**,
27–30 (2000).

126.   Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models
via Coordinate Descent. *J. Stat. Soft.* **33**, (2010).

127.   Lever, J., Krzywinski, M. & Altman, N. Classification evaluation. *Nat Methods* **13**, 603–604
(2016).

128.   DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more
correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics* **44**, 837–
845 (1988).

129.   Purcell, S. M. & Chang, C. C. PLINK v1.9. www.cog-genomics.org/plink/1.9/.

130.   Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2**, 6 (2022).

131.   Skrivankova, V. W. *et al.* Strengthening the Reporting of Observational Studies in
Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. *JAMA* **326**, 1614 (2021).

132.   Hartwig, F. P., Davies, N. M., Hemani, G. & Davey Smith, G. Two-sample Mendelian
randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible
technique. *International Journal of Epidemiology* **45**, 1717–1726 (2016).

133.   Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian
randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int. J. Epidemiol.*
dyw220 (2016) doi:10.1093/ije/dyw220.

134.   Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian Randomization Analysis With
Multiple Genetic Variants Using Summarized Data. *Genetic Epidemiology* **37**, 658–665 (2013).

135.   Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the
human phenome. *eLife* **7**, e34408 (2018).

136.   Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression. *International Journal of*
Epidemiology **44**, 512–525 (2015).

137.   Greco M, F. D., Minelli, C., Sheehan, N. A. & Thompson, J. R. Detecting pleiotropy in
Mendelian randomisation studies with summary data and a continuous outcome. *Statistics in*
Medicine **34**, 2926–2940 (2015).

138.   Bowden, J. *et al.* Improving the accuracy of two-sample summary-data Mendelian
randomization: moving beyond the NOME assumption. *International Journal of Epidemiology* **48**,
728–742 (2019).

139.   Berisa, T. & Pickrell, J. K. Approximately independent linkage disequilibrium blocks in human
populations. *Bioinformatics* **32**, 283–285 (2016).

140.   De Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set
Analysis of GWAS Data. *PLoS Comput Biol* **11**, e1004219 (2015).

1256

1257

1258

1259